Allogene Therapeutics, Inc.
- Open
- 2.05
- Day high
- 2.18
- Day low
- 2.05
- Prev close
- 2.08
- Volume
- 7.3M
- Mkt cap
- $742M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 2.7
- P/S
- —
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$22K over the last 3 months (0 open-market buys, 1 sale)
- 🏛Institutions accumulating (13F)
Allogene Therapeutics, Inc. (ALLO) is a Healthcare company listed on NASDAQ. The stock is up 76% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 1 sale (SEC Form 4).
Allogene Therapeutics, Inc. (ALLO) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 6 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
ALLO earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 13, 2026 | $-0.19 | $-0.18 | +5.3% | — | — |
| Mar 12, 2026 | $-0.23 | $-0.17 | +24.6% | — | — |
| Nov 6, 2025 | $-0.23 | $-0.19 | +17.4% | — | — |
| Aug 13, 2025 | $-0.28 | $-0.23 | +17.9% | — | — |
| Mar 13, 2025 | $-0.34 | $-0.28 | +17.6% | $22000 | +83.3% |
| Nov 7, 2024 | $-0.34 | $-0.27 | +20.6% | — | — |
| Mar 14, 2024 | $-0.47 | $-0.43 | +8.5% | $21000 | +5.0% |
| Nov 2, 2023 | $-0.53 | $-0.37 | +30.2% | $43000 | +115.0% |
| Aug 2, 2023 | $-0.59 | $-0.53 | +10.2% | $44000 | +120.0% |
| May 3, 2023 | $-0.63 | $-0.68 | -7.9% | $52000 | +420.0% |
| Feb 28, 2023 | $-0.71 | $-0.66 | +7.0% | $47000 | -39.1% |
| Nov 2, 2022 | $-0.62 | $-0.58 | +6.5% | $49000 | +583.7% |
ALLO insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 23, 2026 | Barrett Elizabeth A.director | Grant | 95,400 | — |
| Jun 23, 2026 | WITTE OWEN N.director | Grant | 95,400 | — |
| Jun 23, 2026 | SATO VICKI Ldirector | Grant | 95,400 | — |
| Jun 23, 2026 | Mayo Stephendirector | Grant | 144,400 | $2.00 |
| Jun 23, 2026 | MESSEMER DEBORAH M.director | Grant | 95,400 | — |
| Jun 23, 2026 | Kazam Joshua Adirector | Grant | 95,400 | — |
| Jun 23, 2026 | Kazam Joshua Adirector | Option | 47,700 | — |
| Jun 23, 2026 | Humer Franz Bdirector | Grant | 95,400 | — |
| Apr 23, 2026 | Yoshiyama Annieofficer: SVP, Finance | Sell | 9,586 | $2.31 |
| Apr 2, 2026 | Beneski Benjamin Machinasofficer: SVP, Chief Technical Officer | Sell | 2,867 | $2.50 |
| Mar 18, 2026 | Beneski Benjamin Machinasofficer: SVP, Chief Technical Officer | Sell | 4,835 | $2.47 |
| Mar 18, 2026 | Chang David Ddirector, officer: President and CEO | Sell | 47,763 | $2.47 |
| Mar 4, 2026 | Beneski Benjamin Machinasofficer: SVP, Chief Technical Officer | Sell | 7,132 | $2.60 |
| Feb 4, 2026 | Yoshiyama Annieofficer: SVP, Finance | Grant | 50,827 | — |
| Feb 4, 2026 | Yoshiyama Annieofficer: SVP, Finance | Grant | 179,691 | $1.87 |
Source: ALLO SEC Form 4 filings, latest Jun 23, 2026. For informational purposes only — not investment advice.
See the full ALLO insider & 13F page →Allogene Therapeutics, Inc. company profile
Overview
Allogene Therapeutics, Inc. (NASDAQ:ALLO) is a clinical-stage immuno-oncology biotechnology company founded in 2017 and headquartered in South San Francisco, California. The company went public in October 2018 and has positioned itself as a pioneer in developing "off-the-shelf" allogeneic CAR T cell therapies for cancer treatment and autoimmune diseases. Unlike traditional CAR T therapies that require extracting and modifying a patient's own immune cells, Allogene's approach uses genetically engineered T cells from healthy donors that can be manufactured in advance and stored for immediate use when needed.
Business
Allogene operates in the cell therapy segment of biotechnology, specifically developing allogeneic CAR T cell therapies. To understand this complex field, it's important to know that CAR T (Chimeric Antigen Receptor T-cell) therapy is a form of immunotherapy where T cells (a type of immune cell) are genetically modified to better recognize and attack cancer cells. Traditional CAR T therapy is "autologous," meaning doctors extract T cells from the patient, modify them in a laboratory, and then infuse them back into the same patient - a process that can take weeks and costs hundreds of thousands of dollars. Allogene's innovation lies in developing allogeneic CAR T therapies, which use T cells from healthy donors rather than the patient themselves. These "off-the-shelf" therapies can be manufactured in advance, stored frozen, and administered immediately when needed, potentially making treatment faster, more accessible, and less expensive. The company's pipeline includes several product candidates targeting different diseases: 1. ALLO-501A (ALPHA3 trial) - targeting CD19-positive large B-cell lymphoma, currently in a pivotal Phase II trial for first-line consolidation treatment. This represents the company's most advanced program with potential for regulatory approval by 2027. 2. ALLO-329 - a dual CD19/CD70 targeting therapy for autoimmune diseases, representing the company's expansion beyond cancer into conditions like rheumatoid arthritis and lupus. This program aims to potentially eliminate the need for lymphodepletion (chemotherapy conditioning). 3. ALLO-316 - targeting CD70 for renal cell carcinoma (kidney cancer), showing promising early results with a 33% confirmed response rate in solid tumors. 4. ALLO-715 - targeting BCMA for multiple myeloma treatment, currently undergoing manufacturing process improvements. The company has developed proprietary technologies including Dagger Technology for improved CAR T cell persistence and the Alloy manufacturing process for consistent production at their Cell Forge facility.
Revenue model
Allogene's business model is built around developing and eventually commercializing allogeneic CAR T cell therapies, with revenue expected to come primarily from product sales to hospitals and cancer treatment centers once their therapies receive regulatory approval. Currently, the company generates minimal revenue (less than $100,000 annually) from collaboration agreements and licensing deals with partners like Pfizer, Servier, and Cellectis. The company's paying customers will be healthcare institutions - hospitals, cancer centers, and specialty clinics that treat cancer patients and autoimmune diseases. Unlike traditional pharmaceuticals sold directly to patients, CAR T therapies are complex treatments administered in specialized medical facilities by trained oncologists and hematologists. The business model faces several margin-influencing factors. Positive factors include the potential for premium pricing due to the life-saving nature of cancer treatments, the off-the-shelf advantage that could reduce manufacturing costs compared to autologous therapies, and the ability to scale production at their Cell Forge facility to serve approximately 20,000 patients annually. The company's manufacturing approach could create significant cost advantages over individualized CAR T therapies that currently cost $400,000-500,000 per treatment. Challenging factors include the high cost of clinical trials and regulatory approval processes (current cash burn of approximately $150 million annually), intense competition from established CAR T companies like Gilead/Kite and Novartis, potential manufacturing complexities in scaling allogeneic cell production, and regulatory risks as the FDA evaluates this relatively new therapeutic approach. Additionally, the company must navigate complex reimbursement negotiations with insurance providers and government healthcare programs, which significantly impact profitability in the cell therapy space.
Competitive moat
Allogene's competitive moat is moderate but developing, built primarily around its technological differentiation and manufacturing capabilities rather than traditional barriers like brand recognition or network effects. The company's primary moat stems from its proprietary allogeneic platform, which includes the Dagger Technology for enhanced CAR T cell persistence and the Alloy manufacturing process that enables off-the-shelf production. The company's Cell Forge manufacturing facility represents a significant competitive advantage, capable of producing approximately 20,000 patient doses annually with consistent quality - a stark contrast to the individualized, time-intensive manufacturing required for autologous CAR T therapies. This manufacturing capability, combined with intellectual property around allogeneic cell engineering, creates barriers for competitors attempting to replicate their approach. However, the moat faces substantial challenges. Large pharmaceutical companies like Gilead Sciences (through Kite Pharma) and Novartis have significantly more resources, established commercial infrastructure, and approved CAR T products already generating billions in revenue. These companies are also developing next-generation CAR T approaches that could potentially match or exceed Allogene's advantages. Regulatory uncertainty presents another moat vulnerability, as allogeneic CAR T therapy is still relatively unproven compared to autologous approaches. The FDA's evaluation process and potential safety concerns could favor established autologous therapies. Additionally, academic institutions and other biotech companies are pursuing similar allogeneic approaches, potentially eroding Allogene's first-mover advantage. The company's expansion into autoimmune diseases with ALLO-329 could strengthen its moat by creating a differentiated market position, as few competitors are pursuing CAR T therapy for non-cancer indications. Success in this area could establish Allogene as the leader in a new therapeutic category with significant market potential.
Risks & safety
The margin of safety is moderate to concerning given the company's pre-revenue status and substantial cash burn, though current liquidity provides near-term stability. **Cash and Solvency:** - Cash and investments of $335.5 million as of Q1 2025 provides runway into second half of 2027 - Annual cash burn of approximately $150 million in 2025, down from $170 million guidance - Strong current ratio of 9.7x indicates excellent short-term liquidity - Minimal debt with debt-to-equity ratio of 0.21 - No immediate solvency risk given current cash position **Valuation Metrics:** - Trading at 0.82x book value, suggesting potential asset value protection - Graham net-net ratio of 0.73, indicating stock trades below liquidation value - Negative earnings make P/E ratios not meaningful - Enterprise value reflects significant discount to invested capital **Other Considerations:** - Clinical-stage biotech with binary risk profile dependent on trial outcomes - ALPHA3 pivotal trial represents major value inflection point expected by 2026-2027 - Regulatory approval risk remains significant for allogeneic CAR T approach - Competition from well-funded pharmaceutical companies with approved products
Recent development
Over the past few years, Allogene has undergone significant strategic evolution, transitioning from a broad-pipeline approach to focused development of three key assets. The company's most significant pivot has been launching the ALPHA3 pivotal trial for ALLO-501A in large B-cell lymphoma, representing their first potentially registrational study. This Phase II trial targets first-line consolidation treatment for patients with minimal residual disease, a novel approach that could establish a new standard of care. The company has made a strategic expansion into autoimmune diseases with ALLO-329, marking the first dual CD19/CD70 targeting allogeneic CAR T therapy for conditions like rheumatoid arthritis and lupus. This program received FDA IND clearance and aims to potentially eliminate lymphodepletion, which would represent a significant advancement in making CAR T therapy more accessible to autoimmune patients. Manufacturing capabilities have been substantially enhanced with the Cell Forge facility optimization and implementation of the proprietary Alloy manufacturing process across multiple programs. The company has also integrated Dagger Technology to improve CAR T cell persistence and potentially reduce the need for intensive conditioning regimens. Recent strategic moves include expanding European rights for cema-cel and exploring potential partnerships for ALLO-316 in renal cell carcinoma, which showed promising 50% best overall response rates and received FDA Regenerative Medicine Advanced Therapy (RMAT) designation. The company has also implemented significant operational efficiency measures, reducing expected cash burn from $190 million to $150 million annually while extending cash runway into 2027.
ALLO company profile · for informational purposes only — not investment advice.
Track ALLO with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free